124 related articles for article (PubMed ID: 29104884)
1. Hepatitis C virus Cell-to-cell Spread Assay.
Barretto N; Uprichard SL
Bio Protoc; 2014 Dec; 4(24):. PubMed ID: 29104884
[TBL] [Abstract][Full Text] [Related]
2. Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.
Barretto N; Sainz B; Hussain S; Uprichard SL
J Virol; 2014 May; 88(9):5050-61. PubMed ID: 24554660
[TBL] [Abstract][Full Text] [Related]
3. HCV Reporter System (Viral Infection-Activated Split-Intein-Mediated Reporter System) for Testing Virus Cell-to-cell Transmission
Zhao F; Zhao T; Deng L; Lv D; Zhang X; Pan X; Xu J; Long G
Bio Protoc; 2018 Aug; 8(15):e2949. PubMed ID: 34395761
[TBL] [Abstract][Full Text] [Related]
4. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
5. Colorimetric focus-forming assay with automated focus counting by image analysis for quantification of infectious hepatitis C virions.
Kang W; Shin EC
PLoS One; 2012; 7(8):e43960. PubMed ID: 22937136
[TBL] [Abstract][Full Text] [Related]
6. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.
Catanese MT; Loureiro J; Jones CT; Dorner M; von Hahn T; Rice CM
J Virol; 2013 Aug; 87(15):8282-93. PubMed ID: 23698298
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Xiao F; Fofana I; Heydmann L; Barth H; Soulier E; Habersetzer F; Doffoël M; Bukh J; Patel AH; Zeisel MB; Baumert TF
PLoS Pathog; 2014 May; 10(5):e1004128. PubMed ID: 24830295
[TBL] [Abstract][Full Text] [Related]
8. Cell-to-Cell Transmission Is the Main Mechanism Supporting Bovine Viral Diarrhea Virus Spread in Cell Culture.
Merwaiss F; Czibener C; Alvarez DE
J Virol; 2019 Feb; 93(3):. PubMed ID: 30404802
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses.
Shimizu YK; Hijikata M; Iwamoto A; Alter HJ; Purcell RH; Yoshikura H
J Virol; 1994 Mar; 68(3):1494-500. PubMed ID: 8107212
[TBL] [Abstract][Full Text] [Related]
10. Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.
Fan H; Qiao L; Kang KD; Fan J; Wei W; Luo G
J Virol; 2017 Jul; 91(13):. PubMed ID: 28404852
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.
Timpe JM; Stamataki Z; Jennings A; Hu K; Farquhar MJ; Harris HJ; Schwarz A; Desombere I; Roels GL; Balfe P; McKeating JA
Hepatology; 2008 Jan; 47(1):17-24. PubMed ID: 17941058
[TBL] [Abstract][Full Text] [Related]
12. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
13. Interactions between the Hepatitis C Virus Nonstructural 2 Protein and Host Adaptor Proteins 1 and 4 Orchestrate Virus Release.
Xiao F; Wang S; Barouch-Bentov R; Neveu G; Pu S; Beer M; Schor S; Kumar S; Nicolaescu V; Lindenbach BD; Randall G; Einav S
mBio; 2018 Mar; 9(2):. PubMed ID: 29535204
[TBL] [Abstract][Full Text] [Related]
14. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.
Witteveldt J; Evans MJ; Bitzegeio J; Koutsoudakis G; Owsianka AM; Angus AG; Keck ZY; Foung SK; Pietschmann T; Rice CM; Patel AH
J Gen Virol; 2009 Jan; 90(Pt 1):48-58. PubMed ID: 19088272
[TBL] [Abstract][Full Text] [Related]
15. Determinants in the Ig Variable Domain of Human HAVCR1 (TIM-1) Are Required To Enhance Hepatitis C Virus Entry.
Kachko A; Costafreda MI; Zubkova I; Jacques J; Takeda K; Wells F; Kaplan G; Major ME
J Virol; 2018 Mar; 92(6):. PubMed ID: 29321304
[TBL] [Abstract][Full Text] [Related]
16. Early infection events highlight the limited transmissibility of hepatitis C virus in vitro.
Meredith LW; Harris HJ; Wilson GK; Fletcher NF; Balfe P; McKeating JA
J Hepatol; 2013 Jun; 58(6):1074-80. PubMed ID: 23353869
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis.
Blackard JT; Kong L; Huber AK; Tomer Y
Thyroid; 2013 Jul; 23(7):863-70. PubMed ID: 23259732
[TBL] [Abstract][Full Text] [Related]
19. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
20. A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
Denolly S; Granier C; Fontaine N; Pozzetto B; Bourlet T; Guérin M; Cosset FL
J Hepatol; 2019 Apr; 70(4):626-638. PubMed ID: 30553840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
